Standardized warfarin monitoring decreases adverse drug reactions

Abstract

BackgroundWhile warfarin is the most commonly prescribed medication to prevent thromboembolic disorders, the risk of adverse drug reactions (ADR) poses a serious concern. This prospective study evaluated how primary care providers (PCP) and cardiologists at our Institution managed patients treated with warfarin with the goal of decreasing the number of warfarin ADRs.MethodsA multidisciplinary anticoagulation task force was established at our Institution in 2014 to standardize warfarin monitoring and management. Between 2013 and 2017, we analyzed patients who were prescribed warfarin by their PCP or cardiologist upon hospital discharge and in the ambulatory setting to determine the international normalized ratio (INR) within 5, 10, and 30\u2009days after discharge, time in therapeutic range (TTR), number of severe warfarin ADRs, and total and average cost reduction of all severe warfarin ADRs to determine whether there was an organizational cost savings following the implementation of standardized warfarin care.ResultsThe warfarin ADR rate significantly decreased over the 5-year period, from 3.8 to 0.98% (p\u2009<\u20090.0001). The proportion of warfarin prescriptions out of all anticoagulants significantly decreased, from 72.2 to 42.1% (p\u2009<\u20090.001). The proportion of individuals who received an INR at 5, 10, and 30\u2009days after hospital discharge compared to the total number of patients prescribed warfarin significantly increased (p\u2009<\u20090.001). The total cost of severe warfarin ADRs decreased by 57.6% between 2013 and 2017.ConclusionsThis study serves as a model to reduce the number of severe warfarin ADRs by the following tactics: (1) educating PCPs and cardiologists about evidence-based guidelines for warfarin management, (2) increasing the use of our Institution’s electronic warfarin module, and (3) enhancing patient compliance with obtaining INR.